HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of generalized anxiety disorder: comparison of a new beta-blocking drug (CGP 361 A), low-dose neuroleptic (flupenthixol), and placebo.

Abstract
In an attempt to evaluate an alternative drug treatment to benzodiazepines in generalized anxiety disorders, a placebo controlled trial was carried out with a new beta-adrenergic blocker (CPG 361 A). A low-dosage neuroleptic (flupenthixol) was included as a reference drug. Depending on the clinical assessment scales the placebo treatment resulted in moderate to excellent improvement in 36% to 56% of the patients after four weeks of treatment. The active drugs generally had a higher improvement range (from 31% to 80%). The global improvement scale was found to be better than the other scales in discriminating between placebo (50% improvement) and the active drugs (CGP 361 A brought about 78% improvement and flupenthixol brought about 80% improvement). However, only for flupenthixol was the difference of statistical significance.
AuthorsH Bjerrum, P Allerup, K Thunedborg, K Jakobsen, P Bech
JournalPharmacopsychiatry (Pharmacopsychiatry) Vol. 25 Issue 5 Pg. 229-32 (Sep 1992) ISSN: 0176-3679 [Print] Germany
PMID1357681 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic beta-Antagonists
  • Anti-Anxiety Agents
  • Propanolamines
  • isamoltane
  • Flupenthixol
Topics
  • Adrenergic beta-Antagonists (therapeutic use)
  • Adult
  • Anti-Anxiety Agents (therapeutic use)
  • Anxiety Disorders (drug therapy, psychology)
  • Double-Blind Method
  • Female
  • Flupenthixol (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Propanolamines (therapeutic use)
  • Psychiatric Status Rating Scales

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: